Advisors Asset Management’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-11,123
Closed -$162K – 1472
2026
Q2
$162K Buy
11,123
+139
+1% +$2.46K ﹤0.01% 1196
2026
Q1
$208K Sell
10,984
-141
-1% -$2.28K ﹤0.01% 1136
2025
Q4
$195K Sell
11,125
-5
-0% -$94 ﹤0.01% 1137
2025
Q3
$230K Sell
11,130
-43
-0.4% -$1.04K ﹤0.01% 1097
2025
Q2
$238K Buy
11,173
+6
+0.1% +$137 ﹤0.01% 1088
2025
Q1
$215K Buy
11,167
+5,021
+82% +$101K ﹤0.01% 1097
2024
Q4
$110K Buy
+6,146
New +$119K ﹤0.01% 1210

Other funds holding SMMT

Advisors Asset Management's SMMT Position: Q3 2026 in Review

Advisors Asset Management sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 11,123 shares — an estimated $162K sold.

Advisors Asset Management first reported a position in SMMT in Q4 2024 and held it in 7 quarters. The position peaked at $238K in Q2 2025. 295 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Advisors Asset Management reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Advisors Asset Management sold 11,123 Summit Therapeutics shares in Q3 2026, an estimated $162K.
  • Advisors Asset Management first reported a position in Summit Therapeutics in Q4 2024 and held it in 7 quarters.
  • Advisors Asset Management's Summit Therapeutics position peaked at $238K in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Advisors Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.